Family history as a risk factor for herpes zoster: A case-control study

Archives of Dermatology

Volumn 144, Issue 5, 2008, Pages 603-608

  Hicks, Lindsey D ^e,f   Cook Norris, Robert H ^a   Mendoza, Natalia ^b,c   Madkan, Vandana ^c   Arora, Anita ^c   Tyring, Stephen K ^c,d  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

^c CENTER FOR CLINICAL STUDIES   (United States)

^d University of Texas Health Science Center at Houston   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; VACCINATION; VARICELLA ZOSTER VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FAMILY HEALTH; FEMALE; HERPES ZOSTER; HUMANS; INTERVIEWS AS TOPIC; LOGISTIC MODELS; MALE; MEDICAL RECORDS; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS;

EID: 44249108080     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.5.603     Document Type: Article

References (26)

1. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26-33.
2. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62(9):1545-1551.
3. McCrary M, Brown TJ, Tyring SK. Varicella zoster virus. In: Tyring SK, ed. Mucocutaneous Manifestations of Viral Diseases. New York, NY: Marcel Dekker; 2002:119-144.
4. Goldman GS. Cost-benefit analysis of universal varicella vaccination in the US taking into account the closely related herpes-zoster epidemiology. Vaccine. 2005;23(25):3349-3355.
5. Haanpää M, Nurmikko T, Hurme M. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis. 2002;34(2):112-114.
6. Cooke GS, Hill AV. Genetics of susceptibility to human disease. Nat Rev Genet. 2001;2(12):967-977.
7. Hill AV. The genomics and genetics of human infectious disease susceptibility. Annu Rev Genomics Hum Genet. 2001;2:373-400.
8. Ghodke Y, Joshi K, Chopra A, Patwardhan B. HLA and disease. Eur J Epidemiol. 2005;20(6):475-488.
9. Segal S, Hill AV. Genetics susceptibility to infectious disease. Trends Microbiol. 2003;11(9):445-448.
10. Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Semin Immunol. 2006;18(6):387-403.
11. Jülg B, Goebel FD. Susceptibility to HIV/AIDS: an individual characteristic we can measure? Infection. 2005;33(3):160-162.
12. den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: a protective role for HLA-B27. AIDS Rev. 2004;6(2):89-96.
13. Kernich CA. Shingles. Neurologist. 2007;13(1):43-44.
14. Vicari AP, Trinchieri G. Interleukin-10 in viral disease and cancer: exiting the labyrinth? Immunol Rev. 2004;202:223-236.
15. Cottoni F, Masala MV, Santarelli R, et al. Susceptibility to human herpesvirus-8 infection in a healthy population from Sardinia is not directly correlated with the expression of HLA-DR alleles. Br J Dermatol. 2004;151(1):247-248.
16. Ozawa A, Sasao Y, Iwashita K, et al. HLA-A33 and -B44 and susceptibility to post-herpetic neuralgia (PHN). Tissue Antigens. 1999;53(3):263-268.
17. Seppanen M, Meri S, Notkola IL. Subtly impaired humoral immunity predisposes to frequently recurring genital herpes simplex virus type 2 infection and herpetic neuralgia. J Infect Dis. 2006;194(5):571-578.
18. Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine. 2003;21(19-20):2541-2547.
19. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001;33(1):62-69.
20. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360(9334):678-682.
21. Lerman Y, Chodick G, Tepper S, Livini G, Ashkenazi S. Seroepidemiology of varicella-zoster virus antibodies among health-care workers and day-care workers. Epidemiol Infect. 2004;132(6):1135-1138.
22. Schmader K, George LK, Burchett BM, Pieper CF. Racial and psychosocial risk factors for herpes zoster in the elderly. J Infect Dis. 1998;178(1)(suppl 1):S67-S70.
23. Schmader K, George LK, Burchet BM, Hamilton JD, Pieper CF. Race and stress in the incidence of herpes zoster in older adults. J Am Geriatr Soc. 1998;46(8):973-977.
24. Acharya N, Lietman T, Cevallos V, et al. Correlation between clinical suspicion and polymerase chain reaction verification of infectious vitritis. Am J Ophthalmol. 2006;141(3):584-585.
25. Lautenschlager S. Herpes simplex and varicella zoster virus infections. Ther Umsch. 2003;60(10):605-614.
26. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.